ALN-VSP

**ALN-VSP** is an investigational, systemically administered lipid-nanoparticle RNA interference therapeutic developed for liver cancers and advanced solid tumors involving the liver. The product contains two chemically modified small interfering RNAs directed against **vascular endothelial growth factor A** and **kinesin family member 11**, also known as kinesin spindle protein. By inducing RNA interference-mediated degradation of the corresponding messenger RNAs, ALN-VSP is intended to suppress tumor angiogenesis through VEGF-A reduction and inhibit mitosis and tumor-cell proliferation through KIF11 reduction. Alnylam evaluated intravenous ALN-VSP02 in a Phase I study and licensed China, Hong Kong, Macau, and Taiwan development rights to Ascletis, which used the internal designation ASC06.

Other names

anti-KSP/anti-VEGF siRNAs